BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 31079257)

  • 1. Tumor growth patterns on magnetic resonance imaging and treatment outcomes in patients with locally advanced cervical cancer treated with definitive radiotherapy.
    Tsuruoka S; Kataoka M; Hamamoto Y; Tokumasu A; Uwatsu K; Kanzaki H; Takata N; Ishikawa H; Ouchi A; Mochizuki T
    Int J Clin Oncol; 2019 Sep; 24(9):1119-1128. PubMed ID: 31079257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcome and toxicity of radical radiotherapy or concurrent Chemoradiotherapy for elderly cervical cancer women.
    Wang W; Hou X; Yan J; Shen J; Lian X; Sun S; Liu Z; Meng Q; Wang D; Zhao M; Qiu J; Hu K; Zhang F
    BMC Cancer; 2017 Aug; 17(1):510. PubMed ID: 28764676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic model based on magnetic resonance imaging, whole-tumour apparent diffusion coefficient values and HPV genotyping for stage IB-IV cervical cancer patients following chemoradiotherapy.
    Lin G; Yang LY; Lin YC; Huang YT; Liu FY; Wang CC; Lu HY; Chiang HJ; Chen YR; Wu RC; Ng KK; Hong JH; Yen TC; Lai CH
    Eur Radiol; 2019 Feb; 29(2):556-565. PubMed ID: 30051142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment response evaluation using the mean apparent diffusion coefficient in cervical cancer patients treated with definitive chemoradiotherapy.
    Onal C; Erbay G; Guler OC
    J Magn Reson Imaging; 2016 Oct; 44(4):1010-9. PubMed ID: 26919800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of ADC quantification for clinical outcome in uterine cervical cancer treated with concurrent chemoradiotherapy.
    Gu KW; Kim CK; Choi CH; Yoon YC; Park W
    Eur Radiol; 2019 Nov; 29(11):6236-6244. PubMed ID: 30980126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk assessment model for overall survival in patients with locally advanced cervical cancer treated with definitive concurrent chemoradiotherapy.
    Shim SH; Lee SW; Park JY; Kim YS; Kim DY; Kim JH; Kim YM; Kim YT; Nam JH
    Gynecol Oncol; 2013 Jan; 128(1):54-59. PubMed ID: 23063760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diffusion-Weighted Magnetic Resonance Imaging as a Predictor of Outcome in Cervical Cancer After Chemoradiation.
    Ho JC; Allen PK; Bhosale PR; Rauch GM; Fuller CD; Mohamed AS; Frumovitz M; Jhingran A; Klopp AH
    Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):546-553. PubMed ID: 28011045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of pretreatment carcinoembryonic antigen after definitive radiotherapy with or without concurrent chemotherapy for squamous cell carcinoma of the uterine cervix.
    Huang EY; Hsu HC; Sun LM; Chanchien CC; Lin H; Chen HC; Tseng CW; Ou YC; Chang HY; Fang FM; Huang YJ; Wang CY; Lu HM; Tsai CC; Ma YY; Fu HC; Wang YM; Wang CJ
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1105-13. PubMed ID: 20932670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of treatment outcomes between squamous cell carcinoma and adenocarcinoma of cervix after definitive radiotherapy or concurrent chemoradiotherapy.
    Hu K; Wang W; Liu X; Meng Q; Zhang F
    Radiat Oncol; 2018 Dec; 13(1):249. PubMed ID: 30558636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Magnetic resonance imaging during definitive chemoradiotherapy can predict tumor recurrence and patient survival in locally advanced cervical cancer: A multi-institutional retrospective analysis of KROG 16-01.
    Lee SW; Lee SH; Kim J; Kim YS; Yoon MS; Jeong S; Kim JH; Lee J; Eom KY; Jeong BK; Sung SY; Lee SJ; Lee JH
    Gynecol Oncol; 2017 Nov; 147(2):334-339. PubMed ID: 28935271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-treatment MRI minimum apparent diffusion coefficient value is a potential prognostic imaging biomarker in cervical cancer patients treated with definitive chemoradiation.
    Marconi DG; Fregnani JH; Rossini RR; Netto AK; Lucchesi FR; Tsunoda AT; Kamrava M
    BMC Cancer; 2016 Jul; 16():556. PubMed ID: 27469349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Curative effect analysis of postoperative concurrent chemoradiotherapy on early-stage cervical cancer patients with intermediate-risk factors].
    Tang Q; Tu YQ; Chen JH; Lyu XJ; Yan DD
    Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):462-466. PubMed ID: 29936774
    [No Abstract]   [Full Text] [Related]  

  • 13. MRI-based volumetric tumor parameters before and during chemoradiation predict tumor recurrence and patient survival in locally advanced cervical cancer: a subgroup analysis of a phase II prospective trial.
    Kang HB; Kim SH; Lee JH; Lee HC; Kang NK; Lee JH
    Int J Clin Oncol; 2024 May; 29(5):620-628. PubMed ID: 38530569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes and prognostic factors in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy.
    Liu J; Tang G; Zhou Q; Kuang W
    Radiat Oncol; 2022 Aug; 17(1):142. PubMed ID: 35978412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting tumor recurrence in patients with cervical carcinoma treated with definitive chemoradiotherapy: value of quantitative histogram analysis on diffusion-weighted MR images.
    Erbay G; Onal C; Karadeli E; Guler OC; Arica S; Koc Z
    Acta Radiol; 2017 Apr; 58(4):481-488. PubMed ID: 27445314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemoradiotherapy followed by consolidation chemotherapy involving paclitaxel and carboplatin and in FIGO stage IIIB/IVA cervical cancer patients.
    Mabuchi S; Isohashi F; Okazawa M; Kitada F; Maruoka S; Ogawa K; Kimura T
    J Gynecol Oncol; 2017 Jan; 28(1):e15. PubMed ID: 27958682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Skeletal Muscle Loss Is an Imaging Biomarker of Outcome after Definitive Chemoradiotherapy for Locally Advanced Cervical Cancer.
    Lee J; Chang CL; Lin JB; Wu MH; Sun FJ; Jan YT; Hsu SM; Chen YJ
    Clin Cancer Res; 2018 Oct; 24(20):5028-5036. PubMed ID: 29959140
    [No Abstract]   [Full Text] [Related]  

  • 18. Value of blood oxygenation level-dependent MRI for predicting clinical outcomes in uterine cervical cancer treated with concurrent chemoradiotherapy.
    Lee J; Kim CK; Gu KW; Park W
    Eur Radiol; 2019 Nov; 29(11):6256-6265. PubMed ID: 31016443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of nedaplatin-based concurrent chemoradiotherapy for FIGO Stage IB2-IVA cervical cancer and its clinical prognostic factors.
    Fujiwara M; Isohashi F; Mabuchi S; Yoshioka Y; Seo Y; Suzuki O; Sumida I; Hayashi K; Kimura T; Ogawa K
    J Radiat Res; 2015 Mar; 56(2):305-14. PubMed ID: 25428244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the prognostic value of F-18 FDG PET/CT metabolic parameters of primary tumors and MRI findings in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy.
    Dag Z; Yilmaz B; Dogan AK; Aksan DU; Ozkurt H; Kızılkaya HO; Arslan D
    Brachytherapy; 2019; 18(2):154-162. PubMed ID: 30594422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.